YuanBio Venture Capital is a Suzhou-based healthcare venture capital firm founded in 2013, focusing on early and growth-stage investments in biotech, medical devices, IVD, and healthcare services. The firm has over USD 1.3 billion in assets under management and 200+ portfolio companies.
41% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (47% of deals). Average disclosed round size is $77.7M (across 15 rounds with reported amounts).
Portfolio
12
Fund Size
—
Top Stage
Series B
Last 12 Mo
2
Team
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
17 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Genhouse | Unknown | — | Jan 2026 |
 AusperBio | Series C | $120M | Jan 2026 |
| AusperBio | Series B | $63M | Sep 2025 |
| AusperBio | Series B | $50M | May 2025 |
| AusperBio | Series B | $73M | Dec 2024 |
| AusperBio | Series A | $37M | Jul 2024 |
 Degron Therapeutics | Series A | $22M | Jun 2022 |
| CCryofocus | Series B | $193M | Jan 2022 |
 Tavotek | Series B | $35M | Nov 2021 |
 Alebund | Series B | $54.5M | Sep 2021 |
| RRecBio | Series B | $227M | Jan 2020 |
 PegBio | Ipo | — | Jan 2020 |
| PegBio | Series E | $122M | Jan 2017 |
 CORE Biomedicine | Series A | $21M | — |
 浩博医药 | Series B | $73M | — |
| JJHL Biotech | Series C | $45.6M | — |
| BBeyang Therapeutics Co., Ltd. | Series A | $30M | — |
Top Co-Investors
Hankang Capital6 shared
CDH Investments5 shared
Flyer One Ventures4 shared
Qiming Venture Partners USA4 shared
GG14 shared
Segra Capital Management2 shared
Legend Star2 shared
Root Ventures2 shared
Oriza2 shared
Next Capital1 shared
Baidu Ventures1 shared
Med-Fine Capital1 shared
Icon Ventures1 shared
Dyee Capital1 shared
Sherpa Healthcare Partners1 shared
Loyal Valley Capital1 shared
3E Bioventures Capital1 shared
HT Capital Limited1 shared
Quan Funds1 shared
Morningside1 shared
Last updated: 7 October 2026